Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 501–600 of 666
The role of hormonal treatment in type 2 diabetes mellitus
Imam, S. K. (2015) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s49625 · Cited by 3
Soidán, F. J. G. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.01.002 · Cited by 2
Hajjaji, I. M., Shah, S. N., Li, Y., Prusty, V., Benabbas, Y., & Home, P. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0052-4 · Cited by 2
Bolli, G. B., Deeb, L. C., Garg, S. K., Leahy, J. L., Mazze, R. S., Owens, D. R., Riddle, M. C., Southerland, P., & Strock, E. S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0179 · Cited by 2
“The use of basal insulin as an appropriate way to initiate insulin therapy in patients with T2D is supported by the 4T Study.(36) In this study, 708 patients with inadequate glycemic control on oral antidiabetes drugs (OADs) were randomized to receive basal, biphasic, or prandial insulin in the first year, and if glyc…”
BackgroundMethodInfluentialInsulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm20144108-119 · Cited by 2
“Но даже при использовании оптимальных доз базального инсулина около 40% пациентов не достигают или не могут длительно поддерживать рекомендуемые цели HbA1c [23].”
Aspectos prácticos en la insulinización del paciente anciano con diabetes
Díaz, M. S. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65004-1 · Cited by 3
Kokić, S., Kokić, V., Krnić, M., Mirić, L., Jovanović, Ž., & Orlić-Crnčević, Ž. (2010) · Diabetologia Croatica · Cited by 2
Hudson, M., & Palermo, N. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-20317-1_14-1 · Cited by 2
Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients
Hirose, T., Awata, T., Yamamoto, Y., & Hemmingsen, M. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389888 · Cited by 4
“Interventions that address postprandial hyperglycemia become increasingly important as diabetes progresses and postprandial glucose control needs to be more directly addressed [6].”
BackgroundLongitudinal trends in HbA1c in diabetes: Stable means can hide meaningful long‐term changes
Rigalleau, V., Benoit, J., Charret, L., Bertrand, C., Foussard, N., Blanco, L., Alexandre, L., Monlun, M., & Mohammedi, K. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3065 · Cited by 2
Prinz, N., Schwandt, A., Borgert, B., Hartmann, B., Kempe, H., Mader, J. K., Merger, S. R., Weber-Lauffer, R., Wosch, F. J., Holl, R. W., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0144 · Cited by 3
Pharmacological therapy of hyperglycaemia in type 2 diabetes mellitus
Bailey, C. J., & Davies, M. J. (2011) · doi:10.1093/med/9780199235292.003.1373 · Cited by 4
Self-citation(SFD), U. P. D. P. P. P. L. S. F. D. D. (2012) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(12)70660-0 · Cited by 2
Kim, Y., Huh, J. H., Lee, M., Kang, E. S., Soo, B., & Lee, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.880164 · Cited by 2
“However, approximately 40% of patients treated with insulin ultimately fail to achieve their target HbA1c levels and require insulin intensification (4).”
BackgroundIndicaciones de la cirugía bariátrica en sujetos con diabetes mellitus tipo 2
Vidal, J., Blanco, J., Jiménez, A., & Flores, L. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)63007-4 · Cited by 3
Patient characteristics of insulin lispro 200 units/mL users in real world setting in Germany
Schloot, N. C., Perez‐Nieves, M., Sapin, H., Kruppert, S., Otto, T., Corrigan, S. M., & de Oliveira, C. P. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1815001 · Cited by 2
Insulin Regimens in Type 2 Diabetes
Margolis, K. L., O’Connor, P. J., & Sperl-Hillen, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0911551 · Cited by 2
Moses, A. C., & Koenen, C. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0186 · Cited by 2
Meta-analysis on insulin treatment for type 2 diabetes: rushed conclusions?
Wägner, A. M., & Mauricio, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1678-z · Cited by 2
Lalic, N. M., & Landers, B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0165 · Cited by 2
Using Insulin in Type 2 Diabetes: In Need of a Renaissance?
Kerr, D. E., & Olateju, T. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500401 · Cited by 3
Technology to Inform Insulin Dose Adjustments: Its Time Is Near
Zisser, H. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0162 · Cited by 2
Which insulin, regimen and device in type 2 diabetes?
(2010) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2010.12.0060 · Cited by 2
Use of Insulin in Outpatient Diabetes Management
Faradji, R. N., de la Maza, E. S., Menchaca, A. P. D.-B., & Sanromán, J. R. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_37 · Cited by 2
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Kesavadev, J., Kalra, S., John, M., Unnikrishnan, A., Joshi, S., Sankar, P., Kumar, A., Jothydev, K., & Basanth, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_23 · Cited by 3
Zainudin, A. M., Rasool, A. H. G., Nor, M. Z. M., Hassan, N. B., Muhamad, R., & Mohamed, W. M. I. W. (2024) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2024.31.2.9 · Cited by 1
“Most individuals on a single insulin injection will need intensification within 3 years of insulin initiation (8).”
BackgroundBedeutung der Insulintherapie bei Menschen mit Diabetes mellitus Typ 2
Jecht, M., Dötsch, I., & Häussler, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01236-3 · Cited by 1
Optimizing Weight Management: A Collaborative Strategy with Clinical Pharmacists
Andy, A., Choudhary, R. P., Andy, D., & Siddalingegowda, S. M. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3104 · Cited by 1
Cuenca, A. M. C., de la Cuadra-Grande, A., Martínez, E. A., Cabello, M. I. E., Cruz, N. M., Cuatrecasas, G., Hermida, Á. B. Á., Navarro, J., Oyagüez, I., & de la Puente, J. B. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.07.007 · Cited by 2
Hypoglycemia in Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_19 · Cited by 2
Rosenkoetter, M. M., Stachura, M. E., Dias, J. K., Wood, E. A., & Brown, D. J. (2015) · Journal of Nursing Measurement · doi:10.1891/1061-3749.23.2.336 · Cited by 1
“…diabetes management” [IDM]), however, HA1c levels exceed 8% (64 mmol/mol) in more than 60% of patients with Type 2 DM (Koro et al., 2004) and more than a third of IDM patients using multiple daily insulin injections (MDII) fail to achieve the 7% (53 mmol/ mol) goal (Holmann et al., 2009).”
BackgroundTakahara, M., Shiraiwa, T., Ohtoshi, K., Kaneto, H., Katakami, N., Matsuoka, T., & Shimomura, I. (2012) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2012.00223.x · Cited by 1
Buysschaert, M., Pâris, I., Selvais, P., Oriot, P., & Preumont, V. (2012) · PubMed · doi:10.2143/acb.67.4.2062668 · Cited by 1
Cho, K. Y., Nakagaki, O., Miyoshi, H., Akikawa, K., & Astumi, T. (2013) · Diabetology International · doi:10.1007/s13340-013-0140-0 · Cited by 1
“In previous reports with continuous subcutaneous insulin infusion (CSII) [9] or BBT [10, 11], increasing the dose of bolus insulin to almost half of the total insulin requirement led to better glycemic control in type 2 diabetic patients.”
BackgroundMonnier, L., & Colette, C. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70278-4 · Cited by 1
Ampudia‐Blasco, F. J., Rico‐Villademoros, F., Cos, X., & Orozco‐Beltrán, D. (2013) · Internal Medicine Inside · doi:10.7243/2052-6954-1-7
“Conversely, after 3 years, all three groups achieved similar levels of A1C with a reduced frequency of hypoglycemia and weight gain in the basal insulin group [22].”
BackgroundAhluwalia, R., & Vora, J. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651411431846 · Cited by 1
Bhattacharjee, A., & Nath, D. C. (2014) · Statistics in Transition New Series · doi:10.59170/stattrans-2014-029 · Cited by 1
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Home, P., Latif, Z., González-Gálvez, G., Prusty, V., & Hussein, Z. B. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.06.005 · Cited by 1
Kemp, T. (2010) · UpSpace Institutional Repository (University of Pretoria) · Cited by 1
Insulina aspart en pacientes con diabetes tipo 2
Fernández‐García, D., & Sebastián-Ochoa, A. (2012) · Avances en Diabetología · doi:10.1016/s1134-3230(12)70022-4 · Cited by 1
Hess, J. S. G. M. A. (2015) · Journal of Nursing & Care · doi:10.4172/2167-1168.1000226 · Cited by 1
Kardiovaskuläre Effekte der Insulintherapie
Pfohl, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0088-3 · Cited by 1
Kim, G., Lee, Y., Kang, E. S., Soo, B., Lee, H., & Lee, B. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.6.1395 · Cited by 1
Stratégie thérapeutique dans le traitement du diabète de type 2
Bauduceau, B., & Bordier, L. (2018) · Time to knit · doi:10.1016/s1155-1941(18)82762-7 · Cited by 1
Santeusanio, A. D., & Bowen, M. M. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0068 · Cited by 1
“(11), prandial insulin intensification was associated with further hypoglycemia and weight gain compared to biphasic or basal insulin treatment with no additional reduction in A1C.”
BackgroundItoh, M., Suzuki, A., Katoh, T., Sawai, Y., Asano, S., Imamura, S., Hayashi, Y., Goto, S., Takahashi, N., & Kawabe, T. (2021) · PubMed Central · doi:10.20407/fmj.2019-023 · Cited by 1
Glycaemic management of type 2 diabetes
Srinivasan, B. T., & Davies, M. J. (2014) · Medicine · doi:10.1016/j.mpmed.2014.09.011 · Cited by 3
Self-citationInsulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00042-8 · Cited by 2
Insulintherapie bei Diabetes mellitus
Lechleitner, M., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Hoppichler, F., Kautzky‐Willer, A., Schernthaner, G., Prager, R., & Wascher, T. C. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0925-1 · Cited by 4
Cai, X., Luo, Y., Han, X., & Ji, L. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131186 · Cited by 1
Formen der Insulintherapie bei Typ-2-Diabetes
Liebl, A. (2012) · Der Diabetologe · doi:10.1007/s11428-012-0886-1 · Cited by 1
Bando, Y., Shima, K., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K., Toya, D., & Tanaka, N. (2015) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2015.51004 · Cited by 1
“However, regarding bolus injections in particular, it was reported that rapid-acting insulin analogues such as insulin Lis or insulin Asp result in preprandial hypoglycemia or weight gain [7] [8], which could be attributable to the pharmacokinetic (PK) and pharmacodynamic (PD) properties of these two rapid-acting insu…”
BackgroundOnuma, T. (2014) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.60.190 · Cited by 1
Practical Aspects of Insulin Therapy
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_6 · Cited by 1
Self-citationImpact of Insulin Detemir Administration Time on Hypoglycemia Rates in Hospitalized Patients
Grelle, J. L., Kutter, S. N., Giruzzi, M. E., & Tawwater, J. C. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2045 · Cited by 2
“Original studies of insulin detemir planned for once-daily administration in the evening but allowed the transition to twicedaily injections due to nocturnal hypoglycemia.(13) One large study comparing the effects of glargine and detemir in outpatients included such regimen modifications in the trial protocol.”
BackgroundUse of Insulin in Outpatient Diabetes Management
Faradji, R. N., Menchaca, A. P. D.-B., & Viadero, M. E. S. D. L. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_35 · Cited by 1
Pérez, A., & Mendoza, L. C. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.12.004 · Cited by 5
Insulin treatment of Type 2 diabetes: a clinical perspective
Bloomgarden, Z. T., Drexler, A., & Handelsman, Y. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00073.x · Cited by 1
Bilous, F. R., & Donnelly, R. (2010) · doi:10.1002/9781444391374.ch11 · Cited by 1
Analyse critique du consensus ADA/EASD 2009 : ‘‘Back to the past and lost in translation’’
Monnier, L., & Colette, C. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70036-5 · Cited by 1
Ernstige hypoglycemieën en cardiovasculaire complicaties: consequenties voor de behandeling?
de Galan, B. E. (2011) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-011-0014-7 · Cited by 1
Commentary On Fasting Versus Postprandial Hyperglycemia As A Treatment Target To Lower Elevated A1C
Gerich, J. E. (2015) · Endocrine Practice · doi:10.4158/ep15954.co · Cited by 1
Monnier, L., & Colette, C. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70091-2 · Cited by 1
Insulin Management in Type 2 Diabetes
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_4 · Cited by 1
Self-citationWeight Gain on Glucose-Lowering Agents
Lakhdar, A. F. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2834-2_32
How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Aloi, J., & McCall, A. L. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch31
Abholz, H., Egidi, G., Müller, U., & Spranger, J. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0433a
A normoglykaemia elérésének korlátai inzulinkezelt 2-es típusú cukorbetegekben
Ferencz, V., Domján, B. A., Gerő, L., Tänczer, T., & Tabák, Á. G. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30239
Glycemic treatment of diabetes mellitus
Kaur, H., & Weinstock, R. S. (2014) · Wiley eBooks · doi:10.1002/9781118887837.ch4
The Role of Bariatric Surgery in Obese Patients with Diabetes: Primary or Rescue Therapy?
Gandikota, P., & Laferrère, B. (2011) · Wiley eBooks · doi:10.1002/9781444340280.ch14
Type 2 Diabetes: Pharmacological Treatment of Hyperglycaemia
Levy, D. E. (2011) · Wiley eBooks · doi:10.1002/9781444391152.ch6
Response to Bloomgarden et al. Insulin treatment of type 2 diabetes: a clinical perspective
Unnikrishnan, A., & Prusty, V. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00092.x
“This was compared with those on once- or twice-daily premixed insulin analogues (plus midday prandial insulin if required) over a 3-year period.(4) Interestingly, head-to-head comparison trials of BIAsp 30 with basal insulin have shown that BIAsp 30 offers superior HbA1c reduction in patients who are inadequately cont…”
MethodEvidence review : liraglutide for the treatment of type 2 diabetes
Cummins, E., Royle, P., Shyangdan, D., & Waugh, N. R. (2011) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33664453 · Cited by 3
Mechanisms of hypoglycaemia related sudden cardiac death in type 2 diabetes mellitus
Chow, E. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Glinkina, I. V. (2013) · Problems of Endocrinology · doi:10.14341/probl201359525-31
Using insulin in people with type 2 diabetes
Morris, D. (2011) · Nurse Prescribing · doi:10.12968/npre.2011.9.10.496
Bloomgarden, Z. T. (2010) · Endocrine Practice · doi:10.4158/ep.16.s2.1 · Cited by 1
The addition of insulin to metformin and sulphonylureas: results of the 4‐T study
Boyle, J., & Fisher, M. (2010) · Practical Diabetes · doi:10.1002/pdi.1427
¿Sabemos ya cuál es la pauta de insulinización más adecuada para el paciente con diabetes tipo 2?
Wägner, A. M. (2010) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(10)70001-2
Farmer, A. A., Lasserson, D. S., & Holman, R. R. (2010) · Diabetologia · doi:10.1007/s00125-010-1679-y
“Eight of 22 trials scored five out of a possible six points in the modified assessment for potential bias; and the database search for the review was carried out in October 2008, 10 months before the results of the Treating to Target in Type 2 Diabetes (4-T) study 3 year data [3] were known.”
BackgroundSelf-citationStrategies for initiating insulin in type 2 diabetes.
Korownyk, C. S., Ivers, N. M., & Allan, G. M. (2011) · PubMed Central
Acute, ambulatory and central blood pressure measurements in diabetes
Wijkman, M. O. (2012) · DiVA (Digitala Vetenskapliga Arkivet)
Lucas, E. G., Rey, V. R., Gutiérrez, J. M. Á., & García, J. J. L. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70433-x
Pérez-Maraver, M., Romero-Meliá, G., & Corchuelo, J. C. (2015) · Avances en Diabetología · doi:10.1016/j.avdiab.2015.01.001
Farid, D., Haidar, A., & RABASA-LHORET, R. P. R. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.03.021 · Cited by 1
Insulin Therapy in Home Health: A Review
Hess, R., & Odle, B. L. (2012) · Home Health Care Management & Practice · doi:10.1177/1084822312458106
“In addition to convenience, basal insulin therapy has been associated with less hypoglycemia and weight gain compared with more complex insulin regimen types.(16) Analog basal insulin (e.”
BackgroundGood control and few hypos possible with basal insulin starts
Siddall, R. (2009) · Practice Nursing · doi:10.12968/pnur.2009.20.12.45578
Recombinant Insulin in Type 2 Diabetes Treatment: Where Are We Now?
Russo, G. T., Villari, P., Romeo, E. L., Giandalia, A., & Cucinotta, D. (2012) · Science Journal of Clinical Medicine · doi:10.11648/j.sjcm.20120101.12
Инсулин деглудек - новый аналог инсулина сверхдлительного действия
Russian Federation (2014)
Ross, S. A., Tildesley, H. D., & Ashkenas, J. (2011)
Gram, J., Henriksen, J. E., Grodum, E., Juhl, H., Hansen, T. B., Christiansen, C. F., Gjessing, H. J., Hansen, H. M., & Beck‐Nielsen, H. (2010)
Variabilité glycémique et hyperglycémie postprandiale : quelle importance au-delà del’HbA1c?
Monnier, L., Colette, C., Wojtusciszyn, A., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30260-1
Comparison of Three Insulin Regimens
Brett, A. S. (2009) · Journal watch · doi:10.1056/jw200911050000001
Kalain, A. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Diabetische Notfallsituationen – die Hypoglykämie
Siegmund, T., & Schumm‐Draeger, P. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1264-y
Von einfach bis flexibel — zur Auswahl stehen drei Strategien: Insulintherapie bei Typ-2-Diabetes
Liebl, A. (2012) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-012-1298-2
Monguillon, P., Gautier, J., & Fontbonne, A. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70126-7
Wu, T., Betty, B., Downie, M. R., Khanolkar, M., Kilov, G., Orr‐Walker, B., Philips, A., Senator, G. B., & Fulcher, G. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(14)70378-x
“Most of the patients in the prandial and basal groups switched to basal–bolus therapy [23].”
Background
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.